This live Symposium is approved for 8.75 AMA PRA Category 1 Credit(s)TM and 8.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM)

Maintenance of Certi fi cati on (MOC) program, 8.5 CNE contact hours, and 8.5 CPE contact hours by the Purdue University College of Pharmacy.

17th AnnualIndy Hematology Review

Organized by:Indy Hematology Educati on, Inc.

Presented by:

Saturday, August 15, 2020The Westi n Indianapolis 241 W. Washington St.Indianapolis, IN 46204

A full day of presentati ons by today’s leaders in Hematology and Hematologic Malignancies

Achieving tomorrow’s outcomes through education today.TM

Register online: www.indyhematologyreview.comRegister online: www.indyhematologyreview.com

Parti cipati ng in the Symposium will aff ect competence, performance and pati ent outcomes in a variety of ways:1. Att endees will be able to implement the most clinically eff ecti ve management strategies for the

various types and stages of lymphoma, leukemia, and multi ple myeloma to improve pati ent care.2. Att endees will know and understand how to apply updated research in the diagnosis and

treatment of Waldenström’s Macroglobulinemia.3. Att endees will know the new advancements in immune check point inhibitors within

hematologic malignancies and use case reports and summary informati on to update their knowledge in hematologic malignancies.

4. Att endees will have knowledge of new treatment regimens for Hematopoieti c Stem Cell transplant and know when to apply relevant treatment and when to avoid.

5. Att endees will know up to date research informati on on benign hematology.6. Att endees will be updated on new management strategies in follicular lymphoma, with updated

fi rst line, second line, and maintenance treatment opti ons.

This Symposium is designed to provide a valuable educati onal experience to keep you informed and up to date about the most important topics in hematology. Stay current with a concise summary of the criti cal data presented at the American Society of Hematology (ASH) annual meeti ng. Network with thought leaders in the fi eld and more than 400 hematology professionals from across the country.

The Indy Hematology Review brings together over 400 hematologists, oncologists, radiologists, physician assistants, oncology RN’s, nurse practi ti oners, pharmacists, medical students, and other allied health professionals to examine signifi cant scienti fi c updates in clinical hematologic research, learn how these updates directly aff ect the study and practi ce of hematology, and discover how new research can be translated into new pati ent care strategies.

Visit the Exhibit HallVisit the exhibit hall to experience the latest technology, services, devices and research in hematology. The exhibit hall off ers an opportunity to learn about a wide range of products and services off ered by pharmaceuti cal companies, medical suppliers, biotechnology companies, healthcare systems, and research-based companies. Stop in for a beverage and snack at the “Physicians’ Lounge” as you visit exhibitors.

Ruemu Birhiray, MD (Chair)CEO, Indy Hematology Educati on, Inc.

Partner and Vice President,Hematology Oncology of Indiana, PC

Michael C. Wiemann, MD, FACP (Co-Chair)President, Providence Hospital

Executi ve Vice President West Region, St. John Providence Health System

Donna Birhiray, OTR, MBAIndy Hematology Educati on, Inc.

Treasurer and COO

Thalia HammondIndy Hematology Educati on, Inc.

Director of Conventi ons

Jennifer Wheeler-Terry, JDIndy Hematology Educati on, Inc.

Secretary

Debbie LocklearMeeti ng Services Unlimited, Inc.

President

Tina Machina, CMPMeeti ng Services Unlimited, Inc.

Director of Conventi ons

INDY HEMATOLOGY EDUCATION, INC.Achieving tomorrow’s outcomes through education today.TM

Indy Hematology Educati on, Inc. is a 501(c), non-profi t corporati on, incorporated on February 15, 2010, in the State of Indiana, with the following purposes:

(a) Raise awareness and provide educati on regarding hematology and oncology diseases and disorders

(b) To encourage youth to pursue careers in hematology and oncology and

(c) To connect individuals suff ering from or aff ected by hematology and oncology diseases and disorders to organizati ons, programs, and service providers.

PLANNING COMMITTEESUPPORTERS & SPONSORSHIPS

AbbVieAcceleron

AgiosAlexion Pharmaceuti cals

AmgenAstraZenecaBeiGene Ltd

Bristol-Myers SquibbBTG Internati onal, Inc

Clovis OncologyCoherus BioSciences

ExelixisFoundati on Medichine

Genentech

ImmunomedicsIncyte Corporati onJanssen Oncology

Jazz Pharmaceuti calsKyowa Kirin

Novo Nordisk, IncPfi zer, Inc.

PharmacyclicsRigel Pharmaceuti cals

Seatt le Geneti csSanofi Genzyme

Stemline Therapeuti csTakeda

Verastem Oncology

BOARD OF DIRECTORSRuemu E. Birhiray, MD, President and CEO

Michael C. Wiemann, MD, FACP, Vice-PresidentDonna M. Birhiray, OT, MBA, Treasurer and COO

Jennifer Terry, JD, SecretaryThalia Hammond, Director of Conventi ons

Indiana Community Cancer Care Foundati on, Inc

The 2020 Indy Hematology Review is supported by educati onal grants from:

AstraZenecaCelgene Corporati on

PharmacyclicsNovarti s

Seatt le Geneti cs

The 2020 Indy Hematology Review is supported by:

Register online: www.indyhematologyreview.com

7:00 AM – 2:30 PM – Registrati on

7:00 AM – 4:45 PM – Exhibit displays

7:30 AM – Breakfast Product Theaters

8:30 AM – State of the Art: 2020 Emerging Therapies in Hematologic MalignanciesRuemu E. Birhiray, MD – ChairCEO, Indy Hematology Educati on, Inc.Associate Professor of Clinical Medicine, Marian University of Osteopathic Medicine Partner and Vice President, Hematology Oncology of Indiana, PC (Indianapolis, IN)

9:00 AM – Emerging Treatment Paradigms in Multi ple Myeloma: Targeti ng the Neighborhood and Beyond Kenneth Anderson, MDKraft Family Professor of Medicine, Harvard Medical School Program Director of the Lebow Insti tute for Myeloma Therapeuti cs and Jerome Lipper Multi ple Myeloma Center, Dana-Farber Cancer Insti tute (Boston, MA)

9:30 AM – Waldenström’s Macroglobulinemia: Choosing Wisely in Prognosti cati on and Treatment in 2020Steven Treon, MD, MA, PhD, FACP, FRCPAssociate Professor of Medicine, Harvard Medical School Senior Att ending Physician for Medical Oncology at DFCI and Brigham & Women’s HospitalDirector of the Bing Center for Waldenström’s Macroglobulinemia Dana-Farber Cancer Insti tute (Boston, MA)

10:00 AM – Chronic Myeloid Leukemia: Therapeuti c Goals and Managing ResistanceRichard Larson, MDProfessor of Medicine in Hematology/Oncology, Director of Hematologic Malignancies Clinical Research Program The University of Chicago Comprehensive Cancer Center (Chicago, IL)

10:30 AM – Break with Q & A

10:45 AM – Who, When and How to Treat: The Paradox of Watching, Treatment and Retreatment in Indolent Lymphomas in 2020Bruce Cheson, MD, FACP, FAAS, FASCOProfessor of Medicine, Head of Hematology and Cellular Therapy Deputy Chief, Hematology Oncology, and Fellowship Program Director at Medstar Georgetown University Hospital Lombardi Comprehensive Cancer Center (Washington, DC)

11:15 AM – Current Therapy in Aggressive B and T Cell Lymphomas: An UpdateSonali Smith, MDElwood V. Jensen Professor of Medicine, Interim Secti on Chief of Hematology/Oncology, and Director of the Lymphoma Program at the University of Chicago’s Department of Medicine (Chicago, IL)

11:45 AM – Novel Therapy of Acute Lymphoblasti c Leukemia: DRIVERS, CARS and Targeted TherapyHagop Kantarjian, MDSamsung Disti nguished University Chair in Cancer Medicine, Associate Vice President for Global Academic Programs, Professor and Department Chair, Department of Leukemia, Division of Cancer Medicine The University of Texas MD Anderson Cancer Center (Houston, TX)

12:15 PM – Benign Hematology: Current Treatment of Cytopenias and Coagulopathies Craig Kessler, MDProfessor of Medicine and PathologyDirector of Clinical Coagulati on Laboratory in Department of Laboratory Medicine Lombardi Comprehensive Cancer Center Medstar Georgetown University Medical Center (Washington, DC)

12:45 PM – Q & A

1:00 PM – Lunch Product Theaters

2:00 PM – T.HOWARD LEE KEYNOTE LECTURE: Immunotherapy Hematologic Malignancies: Therapeuti c Cellular Immunotherapy Edward Stadtmauer, MDProfessor of Medicine and Secti on Chief of the Hematologic Malignancies in the Division of Hematology-Oncology at the Hospital of the University of Pennsylvania (Philadelphia, PA)

3:00 PM – Challenging Cases Presentati onMichael C. Wiemann, MD, FACP – Co-ChairPresident of Providence Hospital Executi ve Vice President West Region, St. John Providence Health System (Warren, MI)

3:25 PM – Chronic Lymphocyti c Leukemia: Who, When and How to Treat in 2020Steven Coutre, MDProfessor of Medicine in Hematology, Stanford University Medical Center (Palo Alto, CA)

3:55 PM – A Global Perspecti ve of Current Treatment Strategies of Myeloproliferati ve NeoplasmsRami Komrokji, MDSenior Member, Leukemia and MDS Secti onHead Vice Chair, Department of Hematologic Malignancies, Moffi tt Cancer Center (Tampa, FL)

4:25 PM – Break with Q & A

4:40 PM – Bad Blood: Treatment of Complimenti nopathies and Aplasti c AnemiaRobert Brodsky, MDDirector of Division of Hematology Johns Hopkins Family Professor of Medicine and Oncology Johns Hopkins University School of Medicine (Balti more, MD)

SYMPOSIUM AGENDA

Register online: www.indyhematologyreview.com

8:30 AM – State of the Art: 2020 Emerging Therapies in Hematologic MalignanciesRuemu E. Birhiray, MD – Chair

9:00 AM – Management of Long-Term Survivors of Hematologic MalignanciesKristi Orbaugh, RN, MSN RNP, AOCNAdult Nurse Practi ti oner Community Hospital Oncology Physicians (Indianapolis, IN)

9:30 AM – Benign Hematology and CoagulopathyCraig Kessler, MD

10:00 AM – Break with Q & A

10:10 AM – Aggressive LymphomasSonali Smith, MD

10:40 AM – Chronic Leukemias Steven Coutre, MD

11:10 AM – Break with Q & A

11:20 AM – Myeloproliferati ve Neoplasms: Diagnosis, Prognosti cati on and Treatment Opti onsRami Komrokji, MD

11:45 AM – Indolent Lymphomas and Hodgkin’s LymphomaBruce Cheson, MD, FACP, FAAS, FASCO

12:10 PM – Managing Drug Interacti on with Oral Oncolyti cs in the Management of Hematologic MalignanciesDavid Reeves, PharmD, BCOPAssociate Professor of Pharmacy Practi ce, College of Pharmacy and Health Sciences, Butler University Clinical Pharmacy Specialist in Hematology/Oncology, Franciscan Physician Network Oncology/Hematology Specialist (Indianapolis, IN)

12:35 PM – Multi ple Myeloma and Waldenström’sMorie Gertz, MD

12:55 PM – Break with Q & A

1:00 PM – Lunch: Product Theaters

2:00 PM – Adjourn and join General Session for T. Howard Lee Lecture

NURSING AND ALLIED PROVIDERS SYMPOSIUM AGENDA

Disclosure informati on, biographies, and slides (where authorized by the presenter)will be available at indyhematologyreview.com

5:10 PM – Acute Myeloid Leukemia: Prognosti cati on, Targeti ng and Sequencing TherapiesMarti n Tallman, MDChief of Leukemia Service and Professor of Medicine Memorial Sloan-Kett ering Cancer Center Weill Cornell Medical College (New York, NY)

5:40 PM – Myelodysplasti c Syndrome:What is New in 2020?Richard Stone, MDChief of Staff and Director of Translati onal Research, Adult Leukemia ProgramProfessor of Medicine, Harvard Medical School Dana-Farber Cancer Insti tute (Boston, MA)

6:10 PM – How I Treat: The Practi ce of Hematopoieti c Stem Cell Transplantati on in 2020Richard Childs, MD, RADM, USPHSClinical Director, Nati onal Heart, Lung, and Blood Insti tute (NHLBI) Nati onal Insti tutes of Health (Bethesda, MD)

6:40 PM – Break

7:00 PM – Town Hall Recepti on

7:00 PM – 8:30 PM – Hematologic Malignancies Town HallRuemu E. Birhiray, MD. ChairMorie Gertz, MD, MACPSteve Courte, MDCharles Schiff er, M.DRami Komrokji, MDIrene Ghobrial, MD

MODERATORS: Donna M. Birhiray, OTR, MBA and Thalia Hammond

Register online: www.indyhematologyreview.com

To register online, go to indyhematologyreview.comand click on “Register.”

Early Bird Registrati on: ends July 21, 2020Early Bird Physicians $225.00Early Bird Allied Health & Nurses $150.00Early Bird Nurse Practi ti oners & Pharmacists $175.00Industry & Exhibitors $375.00Student/Fellow Scholarship* (Limited Number) $50.00Nurse Scholarship* (Limited Number) $50.00

Standard Registrati on: aft er July 21, 2020Physicians $275.00Allied Health & Nurses $200.00Nurse Practi ti oners & Pharmacists $225.00Industry & Exhibitors $375.00Student/Fellow Scholarship* (Limited Number) $50.00Nurse Scholarship* (Limited Number) $50.00

*A limited number of scholarships are available on a fi rst-come, fi rst-serve basis, based on approval.

NOTE: When registering healthcare providers from your offi ce, fi ll in the person’s full name and email address so thepost-event survey and certi fi cate for conti nuing educati on credits are emailed directly to each person.

REGISTRATION

REFUND POLICYRequest a registrati on cancellati on refund on or before July 30, 2020, to receive a Full Refund. Aft er July 30, 2020, there is NO REFUND.

HOTEL RESERVATIONSMake reservati ons online to reserve a room. You may call The Westi n Indianapolis toll free at 1-800-937-8461.Menti on “Indy Hematology Review” for the discounted group rate of $160 plus tax (currently 17%). The block of discounted rooms will close on Friday, July 30, 2020.

PARKINGParking is available at The Westi n Indianapolis. 24-hour parking rates are currently: $40.00 on-site parking; $45.00 valet (rates are subject to change without noti ce).

Self-parking is also available at the Government Center Washington St. Parking Facility, 401 West Washington Street. Daily Maximum currently: $25.00 (rates are subject to change without noti ce).

PHOTOGRAPHYPhotos of att endees will be taken throughout the Symposium. These photos are for Indy Hematology Review and Indy Hematology Educati on, Inc. use only and may appear on the IHR website, in promoti onal brochures, or other future promoti onal material. By virtue of your att endance, you agree to usage of your photograph in such media, unless we are otherwise noti fi ed in writi ng and receive a clear photo of you.

QUESTIONS?Please contact 317-841-7171,Indyhr@conventi onmanagers.com.

Register online: www.indyhematologyreview.com

CONTINUING EDUCATION INFORMATIONPHYSICIANS

In order to receive CE, you must att end the enti re Symposium from 8:30 am – 6:50 pm. Successful completi on of this CME acti vity requires parti cipants to complete a Post-Evaluati on.

Successful completi on of this CME acti vity, which includes parti cipati on in the evaluati on component, enables the parti cipant to earn up to 8.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certi fi cati on (MOC) program. It is the CME acti vity provider’s responsibility to submit parti cipant completi on informati on to ACCME for the purpose of granti ng ABIM MOC credit.

LEARNING OBJECTIVES (ACCME, ANCC, ACPE)1. Discuss new emerging hematology therapies in general and

for chronic Myeloid Leukemia, acute Promyelocyti c, and Myeloproliferati ve neoplasms.

2. Evaluate molecular diagnosis, targeted therapies, and resistance mechanisms of Waldenström’s Macroglobulinemia to assist in disease recogniti on.

3. Discuss the advancement of immune check point inhibitors within hematologic malignancies and updated treatment paradigms presented at the American Society of Hematology meeti ng in Orlando, FL in December 2019.

4. Recommend new regimens for Hematopoieti c Stem Cell transplantati on and identi fi cati on of transplant candidates.

5. Review the advancement in hematology research and treatment of diseases of coagulopathy, compliment and cytopenia.

6. Review current and emerging treatment regimens in lymphomas.7. Review and update advances in the treatment of disorders of

compliment and aplasti c anemia.8. Present challenging clinical cases and discuss management strategies

of hematologic malignancies and disorders with the applicati on of current and emerging medical literature.

CME ACCREDITATION STATEMENTThis live acti vity has been planned and implemented in accordance with the accreditati on requirements and policies of the Accreditati on Council for Conti nuing Medical Educati on (ACCME) through the joint providership of Purdue University College of Pharmacy and Indy Hematology Educati on, Inc. Purdue University is accredited by the ACCME to provide conti nuing medical educati on for physicians.

DESIGNATION STATEMENTPurdue University College of Pharmacy designates this live acti vity for a maximum of 8.75 AMA PRA Category 1 Credit(s)™.Symposium - 8 am - 6:30 pm. Purdue University College of Pharmacy designates this live acti vity for a maximum of 1.50 AMA PRA Category 1 Credit TM (Town Hall Interacti ve Meeti ng - 7 - 8:30 pm). Physicians should claim only the credit commensurate with the extent of their parti cipati on in the acti vity.

DISCLOSURE STATEMENTAll faculty, staff , and reviewers involved in the planning, review, or presentati on of conti nuing educati on acti viti es provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial fi nancial affi liati ons related to the content of the presentati on or enduring material. Full disclosure of all commercial relati onships must be made in writi ng to the audience prior to the acti vity. All additi onal planning committ ee members, staff , and reviewers of Indy Hematology Educati on, Inc. and Purdue University College of Pharmacy have no relati onships to disclose.

NOTE: While it off ers CME credits, this acti vity is not intended to provide extensive training or certi fi cati on in the fi eld.

NURSESIn order to receive CE, you must att end the enti re Symposium from 8:30 am – 6:50 pm. Successful completi on of this CME acti vity requires parti cipants to complete a Post-Evaluati on.

CNE ACCREDITATION STATEMENTPurdue University Conti nuing Nursing Educati on is accredited as a provider of conti nuing nursing educati on with disti ncti on by the American Nurses Credenti aling Center’s Commission on Accreditati on.

This program is approved for 8.5 contact hours.

(Symposium: 8:30 am - 6:30 pm)This program is approved for 1.50 contact hours(Town Hall Interacti ve Meeti ng: 7 - 8:30 pm).

PHARMACISTSIn order to receive CE, you must att end the enti re Symposium from 8:30 am – 6:50 pm. Successful completi on of this CME acti vity requires parti cipants to complete a Post-Evaluati on.

CPE ACCREDITATION STATEMENTPurdue University College of Pharmacy is accredited by the Accreditati on Council for Pharmacy Educati on as a provider of conti nuing pharmacy educati on. This is a knowledge based, conti nuing educati on acti vity of Purdue University, an equal access/equal opportunity insti tuti on.

Universal Acti vity Number (UAN): 0018-9999-20-001-L01-PThis program is approved for 8.5 contact hours (0.85 CEU’s).Symposium: 8:30 am - 6:30 pm.

Town Hall Interacti ve Meeti ng: 7 - 8:30 pmUniversal Acti vity Number (UAN): 0018-9999-20-002-L01-PThis program is approved for 1.5 contact hours (0.15 CEU’s).

Presented by:

Indy Hematology Review C/O Meeti ng Services Unlimited135 S. Mitt hoeff er Rd.Indianapolis, IN 46229

17th AnnualIndy Hematology Review

Saturday, August 15, 2020The Westi n Indianapolis 241 W. Washington St.Indianapolis, IN 46204

Organized by:Organized by:

Achieving tomorrow’s outcomes through education today.TM